Needham reiterated coverage on CRISPR Therapeutics with a new price target

8/6/24 8:39:51 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Needham reiterated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $84.00 from $88.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRSP

Date	Price Target	Rating	Analyst
2/14/2025	$60.00 → $99.00	In-line → Outperform	Evercore ISI
2/12/2025	$35.00	Sell → Hold	TD Cowen
2/3/2025	$65.00	Buy	H.C. Wainwright
8/6/2024	$88.00 → $84.00	Buy	Needham
8/2/2024	$90.00	Buy	Rodman & Renshaw
6/28/2024		Neutral	Guggenheim
2/15/2024		Peer Perform	Wolfe Research
12/11/2023	$30.00	Market Perform → Underperform	TD Cowen